The relationship between obesity, prostate tumor infiltrating lymphocytes and macrophages, and biochemical failure

PLoS ONE

Volumn 11, Issue 8, 2016, Pages

  Zeigler Johnson, Charnita ^a   Morales, Knashawn H ^b   Lal, Priti ^b   Feldman, Michael ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD68 ANTIGEN; CD8 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; BIOCHEMICAL RECURRENCE; BODY MASS; CANCER GRADING; CONTROLLED STUDY; CORRELATION COEFFICIENT; DEMOGRAPHY; DISEASE SEVERITY; HUMAN; HUMAN TISSUE; KRUSKAL WALLIS TEST; LYMPHOCYTE COUNT; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OBESITY; PATHOLOGY; PILOT STUDY; PROSTATE TUMOR; TUMOR MICROENVIRONMENT; IMMUNOLOGY; METABOLISM; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR ASSOCIATED LEUKOCYTE;

ADULT; AGED; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, CD8; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BIOMARKERS, TUMOR; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; LYMPHOCYTES, TUMOR-INFILTRATING; MACROPHAGES; MALE; MIDDLE AGED; OBESITY; PILOT PROJECTS; PROSTATIC NEOPLASMS; TREATMENT OUTCOME; TUMOR MICROENVIRONMENT;

EID: 84983681676     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0159109     Document Type: Article

References (51)

1. Amling C, Riffenburgh R, Sun L, Moul J, Lance R, Kusuda L, et al. (2004) Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. Journal of Clinical Oncology 22: 439-445. PMID: 14691120
2. Buschemeyer W III, Freedland S (2007) Obesity and prostate cancer: epidemiology and clinical implications. European Association of Urology 52: 331-343.
3. Motamedina P, Korets R, Spencer B, Benson M, McKiernan J (2008) Body mass index and role of obesity in predicting outcome after radical prostatectomy. Urology 72: 1106-1110.
4. Briganti A, Karakiewicz P, Chun F-H, Suardi N, Gallina A, Abdollah F, et al. (2009) Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. International Journal of Urology 16: 676-681. doi: 10.1111/j.1442-2042.2009.02330.x PMID: 19602006
5. Freedland S, Banez L, Sun L, Fitzsimons N, Moul J (2009) Obese men have higher-grade and larger tumors: an analysis of the Duke Prostate Center database. Prostate Cancer and Prostatic Diseases 12: 259-263. doi: 10.1038/pcan.2009.11 PMID: 19581922
6. Spangler E, Zeigler-Johnson C, Coomes M, Malkowicz S, Wein A, Rebbeck T (2007) Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. The Journal of Urology: 1939-1945.
7. Rodriguez C, Freedland S, Deka A, Jacobs E, McCullough M, Patel A, et al. (2007) Body mass index, weight change, and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort Cancer Epidemiol Biomarkers Prev 161: 63-69.
8. Gross M, Ramirez C, Luthringer D, Nepomuceno E, Vollmer R, Burchette J, et al. (2009) Expression of androgen and estrogen related proteins in normal weight and obese prostate cancer patients. The Prostate 69: 520-527. doi: 10.1002/pros.20901 PMID: 19107851
9. Byers T, Sedjo RL (2015) Body fatness as a cause of cancer: epidemiologic clues to biologic mechanisms. Endocr Relat Cancer 22: R125-134. doi: 10.1530/ERC-14-0580 PMID: 25870250
10. Vendramini-Costa DB, Carvalho JE (2012) Molecular link mechanisms between inflammation and cancer. Curr Pharm Des 18: 3831-3852. PMID: 22632748
11. De Pergola G, Silvestris F (2013) Obesity as a major risk factor for cancer. J Obes 2013: 291546. doi: 10.1155/2013/291546 PMID: 24073332
12. Hardaway AL, Herroon MK, Rajagurubandara E, Podgorski I (2014) Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev 33: 527-543. doi: 10.1007/s10555-013-9484-y PMID: 24398857
13. Strong AL, Burow ME, Gimble JM, Bunnell BA (2015) Concise review: The obesity cancer paradigm: exploration of the interactions and crosstalk with adipose stem cells. Stem Cells 33: 318-326. doi: 10.1002/stem.1857 PMID: 25267443
14. Galustian C, Vyakarnam A, Elhage O, Hickman O, Dasgupta P, Smith RA (2011) Immunotherapy of prostate cancer: identification of new treatments and targets for therapy, and role of WAP domain-containing proteins. Biochem Soc Trans 39: 1433-1436. doi: 10.1042/BST0391433 PMID: 21936828
15. Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH (2010) Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29: 1093-1102. doi: 10.1038/onc.2009.416 PMID: 19946335
16. Gollapudi K, Galet C, Grogan T, Zhang H, Said JW, Huang J, et al. (2013) Association between tumor-associated macrophage infiltration, high grade prostate cancer, and biochemical recurrence after radical prostatectomy. Am J Cancer Res 3: 523-529. PMID: 24224130
17. Tilg H, Moshen A (2006) Adipocytokines: Mediators linking adipose tissue, inflammation and immunity. Nature Reviews Immunology 6: 772-783. PMID: 16998510
18. Weisberg S, McCann D, Desai M, Rosenbaum M, Leibel R, Ferrante A Jr (2003) Obesity is associated with macrophage accumulation in adipose tissue. The Journal of Clinical Investigation 112: 1796-1808. PMID: 14679176
19. Rebbeck TR, Weber AL, Walker AH, Stefflova K, Tran TV, Spangler E, et al. (2010) Context-dependent effects of genome-wide association study genotypes and macroenvironment on time to biochemical (prostate specific antigen) failure after prostatectomy. Cancer Epidemiol Biomarkers Prev 19: 2115-2123.
20. Zeigler-Johnson C, Morales KH, Spangler E, Chang BL, Rebbeck TR (2013) Relationship of early-onset baldness to prostate cancer in African-American men. Cancer Epidemiol Biomarkers Prev 22: 589-596. doi: 10.1158/1055-9965.EPI-12-0944 PMID: 23532004
21. Khani F, Mosquera JM, Park K, Blattner M, O'Reilly C, MacDonald TY, et al. (2014) Evidence for molecular differences in prostate cancer between African American and Caucasian men. Clin Cancer Res 20: 4925-4934. doi: 10.1158/1078-0432.CCR-13-2265 PMID: 25056375
22. Kalbfleisch J, Prentice R (2002) The Statistical Analysis of Failure Time Data. New York: Wiley.
23. Ebelt K, Babaryka G, Figel A, Pohla H, Buchner A, Stief C, et al. (2008) Dominance of CD4+ lymphocytic infiltrates with disturbed effector cell characteristics in the tumor microenvironment of prostate carcinoma. The Prostate 68: 1-10. PMID: 17948280
24. Gannot G, Richardson AM, Rodriguez-Canales J, Pinto PA, Merino MJ, Chuaqui RF, et al. (2011) Decrease in CD8+ lymphocyte number and altered cytokine profile in human prostate cancer. Am J Cancer Res 1: 120-127. PMID: 21969236
25. Kiniwa Y, Miyahara Y, Wang H, Peng W, Peng G, Wheeler T, et al. (2007) CD8+ Foxp3+ regulatory T cells mediate immunosuppression in prostate cancer. Clin Cancer Res 13: 6947-6958. PMID: 18056169
26. Kmiecik J, Poli A, Brons NH, Waha A, Eide GE, Enger PO, et al. (2013) Elevated CD3+ and CD8+ tumor-infiltrating immune cells correlate with prolonged survival in glioblastoma patients despite integrated immunosuppressive mechanisms in the tumor microenvironment and at the systemic level. J Neuroimmunol 264: 71-83. doi: 10.1016/j.jneuroim.2013.08.013 PMID: 24045166
27. Strasner A, Karin M (2015) Immune Infiltration and Prostate Cancer. Front Oncol 5: 128. doi: 10.3389/fonc.2015.00128 PMID: 26217583
28. Zlobec I, Minoo P, Terracciano L, Baker K, Lugli A (2011) Characterization of the immunological microenvironment of tumour buds and its impact on prognosis in mismatch repair-proficient and -deficient colorectal cancers. Histopathology 59: 482-495. doi: 10.1111/j.1365-2559.2011.03975.x PMID: 22034888
29. Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, et al. (2013) The ratios of CD8+ T cells to CD4+CD25+ FOXP3+ and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PLoS One 8: e80063. doi: 10.1371/journal.pone.0080063 PMID: 24244610
30. Tiainen S, Tumelius R, Rilla K, Hamalainen K, Tammi M, Tammi R, et al. (2015) High numbers of macrophages, especially M2-like (CD163-positive), correlate with hyaluronan accumulation and poor outcome in breast cancer. Histopathology 66: 873-883. doi: 10.1111/his.12607 PMID: 25387851
31. Mukhtar RA, Moore AP, Tandon VJ, Nseyo O, Twomey P, Adisa CA, et al. (2012) Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer. Ann Surg Oncol 19: 3979-3986. doi: 10.1245/s10434-012-2415-2 PMID: 22622474
32. Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, et al. (2015) Designing a broad-spectrum integrative approach for cancer prevention and treatment. Semin Cancer Biol 35 Suppl: S276-304. doi: 10.1016/j.semcancer.2015.09.007 PMID: 26590477
33. Santoni M, Piva F, Scarpelli M, Cheng L, Lopez-Beltran A, Massari F, et al. (2015) The origin of prostate metastases: emerging insights. Cancer Metastasis Rev 34: 765-773. doi: 10.1007/s10555-015-9597-6 PMID: 26363603
34. Vral A, Magri V, Montanari E, Gazzano G, Gourvas V, Marras E, et al. (2012) Topographic and quantitative relationship between prostate inflammation, proliferative inflammatory atrophy and low-grade prostate intraepithelial neoplasia: a biopsy study in chronic prostatitis patients. Int J Oncol 41: 1950-1958. doi: 10.3892/ijo.2012.1646 PMID: 23026863
35. Taverna G, Pedretti E, Di Caro G, Borroni EM, Marchesi F, Grizzi F (2015) Inflammation and prostate cancer: friends or foe? Inflamm Res 64: 275-286. doi: 10.1007/s00011-015-0812-2 PMID: 25788425
36. Kruger JM, Wemmert C, Sternberger L, Bonnas C, Dietmann G, Gancarski P, et al. (2013) Combat or surveillance? Evaluation of the heterogeneous inflammatory breast cancer microenvironment. J Pathol 229: 569-578. doi: 10.1002/path.4150 PMID: 23192518
37. Lundholm M, Hagglof C, Wikberg ML, Stattin P, Egevad L, Bergh A, et al. (2015) Secreted Factors from Colorectal and Prostate Cancer Cells Skew the Immune Response in Opposite Directions. Sci Rep 5: 15651. doi: 10.1038/srep15651 PMID: 26503803
38. Blando J, Moore T, Hursting S, Jiang G, Saha A, Beltran L, et al. (2011) Dietary energy balance modulates prostate cancer progression in Hi-Myc mice. Cancer Prev Res (Phila) 4: 2002-2014.
39. Rose DP, Gracheck PJ, Vona-Davis L (2015) The Interactions of Obesity, Inflammation and Insulin Resistance in Breast Cancer. Cancers (Basel) 7: 2147-2168.
40. Ungefroren H, Gieseler F, Fliedner S, Lehnert H (2015) Obesity and cancer. Horm Mol Biol Clin Investig 21: 5-15. doi: 10.1515/hmbci-2014-0046 PMID: 25719336
41. Womack J, Tien PC, Feldman J, Shin JH, Fennie K, Anastos K, et al. (2007) Obesity and immune cell counts in women. Metabolism 56: 998-1004. PMID: 17570264
42. Perez-Hernandez AI, Catalan V, Gomez-Ambrosi J, Rodriguez A, Fruhbeck G (2014) Mechanisms linking excess adiposity and carcinogenesis promotion. Front Endocrinol (Lausanne) 5: 65.
43. Sun X, Casbas-Hernandez P, Bigelow C, Makowski L, Joseph Jerry D, Smith Schneider S, et al. (2012) Normal breast tissue of obese women is enriched for macrophage markers and macrophage-associated gene expression. Breast Cancer Res Treat 131: 1003-1012. doi: 10.1007/s10549-011-1789-3 PMID: 22002519
44. Miyahira AK, Kissick HT, Bishop JL, Takeda DY, Barbieri CE, Simons JW, et al. (2015) Beyond immune checkpoint blockade: new approaches to targeting host-tumor interactions in prostate cancer: report from the 2014 Coffey-Holden prostate cancer academy meeting. Prostate 75: 337-347. doi: 10.1002/pros.22920 PMID: 25358693
45. Jacobsen MJ, Mentzel CM, Olesen AS, Huby T, Jorgensen CB, Barres R, et al. (2016) Altered Methylation Profile of Lymphocytes Is Concordant with Perturbation of Lipids Metabolism and Inflammatory Response in Obesity. J Diabetes Res 2016: 8539057. doi: 10.1155/2016/8539057 PMID: 26798656
46. Valdman A, Jaraj S, Comperat E, Charlotte F, Roupret M, Pisa P, et al. (2010) Distribution of Foxp3-, CD4- and CD8-positive lymphocytic cells in benign and malignant prostate tissue. APMIS 118: 360-365. doi: 10.1111/j.1600-0463.2010.02604.x PMID: 20477811
47. De Ridder J, Julian-Almarcegui C, Mullee A, Rinaldi S, Van Herck K, Vicente-Rodriguez G, et al. (2016) Comparison of anthropometric measurements of adiposity in relation to cancer risk: a systematic review of prospective studies. Cancer Causes Control 27: 291-300. doi: 10.1007/s10552-015-0709-y PMID: 26759333
48. Lysaght J, van der Stok EP, Allott EH, Casey R, Donohoe CL, Howard JM, et al. (2011) Pro-inflammatory and tumour proliferative properties of excess visceral adipose tissue. Cancer Lett 312: 62-72. doi: 10.1016/j.canlet.2011.07.034 PMID: 21890265
49. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, et al. (2010) Cancer and inflammation: promise for biologic therapy. J Immunother 33: 335-351.
50. Casbas-Hernandez P, Sun X, Roman-Perez E, D'Arcy M, Sandhu R, Hishida A, et al. (2015) Tumor intrinsic subtype is reflected in cancer-adjacent tissue. Cancer Epidemiol Biomarkers Prev 24: 406-414. doi: 10.1158/1055-9965.EPI-14-0934 PMID: 25465802
51. Robinson B, Sica G, Liu Y-F, Rohan T, Gertler F, Condeelis J, et al. (2009) Tumor microenvironment of metastasis in human breast carcinoma: A potential prognostic marker linked to hematogenous dissemination. Clin Cancer Res 15: 2433-2441. doi: 10.1158/1078-0432.CCR-08-2179 PMID: 19318480